2seventy Bio Inc   (TSVT)
Other Ticker:  
Price: $4.4700 $-0.05 -1.106%
Day's High: $4.6 Week Perf: -6.29 %
Day's Low: $ 4.32 30 Day Perf: 14.91 %
Volume (M): 346 52 Wk High: $ 10.58
Volume (M$): $ 1,544 52 Wk Avg: $4.35
Open: $4.59 52 Wk Low: $1.54

 Market Capitalization (Millions $) 233
 Shares Outstanding (Millions) 52
 Employees -
 Revenues (TTM) (Millions $) 71
 Net Income (TTM) (Millions $) -223
 Cash Flow (TTM) (Millions $) -138
 Capital Exp. (TTM) (Millions $) 8

2seventy Bio Inc
2seventy Bio Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of various diseases. The company employs advanced genetic and protein engineering techniques to create innovative drug candidates. Their research and development efforts are primarily focused on oncology and rare diseases. 2seventy Bio Inc aims to provide targeted and effective treatments that address critical unmet medical needs.

   Company Address: 60 Binney Street Cambridge 2142 MA
   Company Phone Number: 675-7270   Stock Exchange / Ticker: NASDAQ TSVT


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Business Update

Novo Nordisk Acquires 2seventy Bios Hemophilia A Program and MegaTAL In Vivo Gene Editing Technology

Published Thu, Jun 27 2024 1:54 AM UTC

In a recent development, Novo Nordisk has completed the acquisition of 2seventy Bio's Hemophilia A program and the rights to their innovative in vivo gene editing technology. This transaction signifies Novo Nordisk's efforts to bolster their portfolio in the field of gene editing for the treatment of hematological disorders. This article aims to outline the key facts surroun...

Business Update

Novo Nordisk Acquires Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology from 2seventy bio for up to ...

Published Wed, Jun 26 2024 9:47 PM UTC

In a recent development, Novo Nordisk has completed the acquisition of 2seventy bio, Inc.'s Hemophilia A program and the rights to their in vivo gene editing technology (excluding oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease). This sale marks an important milestone for both companies within the ...

2seventy Bio Inc

2seventy Bio Inc Faces Urgent Challenges Throughout First Quarter of 2024

With the recent release of their first quarter 2024 financial results, biotechnology company 2seventy bio, Inc. is showing promising signs of growth and value creation for their shareholders. The company, headquartered in Cambridge, Massachusetts, has undergone a strategic realignment that prioritizes their groundbreaking cancer therapy, Abecma, leading to positive financial outcomes.
During the financial first quarter of 2024, 2seventy bio experienced a net shortfall of $-52.673 million, a slight increase from the previous year's $-47.021 million. While this may seem concerning at first glance, it is important to note that the company's focus on Abecma has set them on a path towards financial stability and growth. Their CEO, Chip Baird, has expressed optimism about this strategic realignment, believing that it will benefit more patients and ultimately lead to robust revenue growth.

Business Update

A Strategic Reboot: 2seventy bio?s Pursuit for Financial Stability and Enhanced Commercial Growth

Published Wed, May 8 2024 11:47 AM UTC

Biotechnology company 2seventy bio, Inc.?s recent financial and operational strides shed a promising light on their intensified focus on making groundbreaking cancer therapy Abecma more accessible and returning to commercial growth. This strategic realignment was reported in the company's first quarter financial results for 2024, as they continue on an upward trajectory towa...

Business Update

2seventy bio to Report Positive First Quarter 2024 Financial Results, Indicating Strong Growth in Biopharmaceutical Industry

Published Fri, May 3 2024 11:47 AM UTC

The biopharmaceutical industry continues to witness significant advancements and breakthroughs, with companies like 2seventy bio, Inc. at the forefront of innovation. On May 8, 2024, 2seventy bio will announce, through a conference call and webcast, its first quarter financial results for the year 2024. The company's achievements and financial performance during this period ...


2seventy Bio Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
2seventy Bio Inc does not provide revenue guidance.

Earnings Outlook
2seventy Bio Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com